N/A N=40 Assessment of Body Composition and Physical Function
Body Composition · Physical Function
Primary: Fat Mass — 44.71 Kg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=105 Protein Supplementation in Elderly With Sarcopenic Obesity Undergoing Caloric Restriction and Exercise
Sarcopenic Obesity · Aging
Primary: Percentage of Fat-free Mass — 49.6; 50.3; 50.5; 52.5 percentage of fat-free mass — p=0.013
N/A N=30 Nutritional Biomarkers of Sarcopenia
Sarcopenia
Primary: Resting and Maximum Plasma Leucine Concentration — 659; 755; 721; 95 micromoles per liter
N/A N=28 Relative Sarcopenia and Cardiometabolic Risk in Young Adults With Obesity
Overweight and Obesity · Insulin Resistance
Primary: Percent Change in Serum Myostatin Levels From Pre- to 3 Hours Post-exercise — -6.9; 8.5 % change in serum myostatin — p=0.303
Phase 2 N=120 Metformin and Muscle in Insulin-resistant Older Veterans
Prediabetes
Primary: Change in Total Lean Mass From Baseline — 322.8; 697.6; 392.4; 548.0 grams lean mass — p=0.45
Phase 2 N=23 The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity
Obesity · Sarcopenic Obesity · Sarcopenia
Primary: Change in Body Weight — 0.54; 0.04 Kilograms
Phase 2 N=34 Biological Effects of Weight Loss In Older, Obese Women
Obesity · Sarcopenia
Primary: Performance on the 400 Meter Walk — 0.16; 0.02 meters per second — p=<0.05
N/A N=14 Muscle Capillarization and Sarcopenia
Sarcopenia
Primary: Skeletal Muscle Capillarization — 0.4; 0.2 capillaries per muscle fiber — p=0.27
N/A N=76 Integrated Physical Training With Protein Diet in Older Adults With Sarcopenia Symptoms.
Sarcopenia
Primary: Changes in Hand Grip Strength — 29.2; 29.5; 35.3; 30.3 kg — p=<0.05
N/A N=25 Effects of a Resistance Training Program in Older Women With Sarcopenia
Sarcopenia
Primary: Muscle Mass Change: From Dual Energy X-ray Absorptiometry and Bioelectrical Impedance Analsysis - Appendicular Lean Mass (ALM in kg) Divided by Height (Meters-squared)…
N/A N=95 Identifying Therapeutic Targets of Accelerated Sarcopenia
Sarcopenia · Diabetes Mellitus · Aging
Primary: Leg Lean Mass — 0.35; -0.55; -0.80; -0.44 kg — p=<0.01
Phase 4 N=88 Optimizing Body Composition for Function in Older Adults
Obesity · Overweight With Indications for Weight Loss
Primary: Appendicular Non-bone Lean Mass — -2.53; -2.49; -2.04; -1.45 kg
Phase 3 N=83 Lifestyle Intervention and Testosterone Replacement in Obese Seniors
Obesity and Hypogonadism
Primary: Change in the Physical Performance Test — 4.6; 4.9 units on a scale — p=0.58
N/A N=77 The Impact of a Resistance Training Intervention on Blood Pressure Control in Older Adults With Sarcopenia
Sarcopenia · High Blood Pressure · Hypertension
Primary: Change in Blood Pressure — 125.5; 131.4; 125.0; 127.5 mmHg
N/A N=22 Regulation of Muscle Protein Phenotype in Humans With Obesity
Obesity
Primary: Whole-Muscle Protein Synthesis — 0.004; 0.015 %/hr
N/A N=17 TRE With Physical Activity for Weight Management
Pre Diabetes · Overweight and Obesity
Primary: Body Weight Changes Between Week 1 to Week 10 — -2.1; -4.2; -1.3; .1 Percent body weight loss
Phase 2 N=170 A Study of the Safety and Efficacy of MK-0773 in Women With Sarcopenia (Loss of Muscle Mass)(MK-0773-005)
Sarcopenia
Primary: Change From Baseline in Participant Lean Body Mass — 1.26; 0.29 kg
N/A N=68 Blood Flow, Muscle Regeneration and Sarcopenia
Sarcopenia
Primary: Muscle Satellite Cells — 3.2; 3.2; 4.0; 3.8 Number of Pax7+ cells/muscle fiber
N/A N=50 Bariatric Surgery for Morbid Obesity
Obesity · Morbid Obesity
Primary: Size of Adipocytes — 73.4; 99.0; 103.0 µm
N/A N=12 Metabolic Syndrome and Fall Risk
Metabolic Syndrome · Autonomic Neuropathy
Primary: Four Square Step Test (FSST) — 11.04; 14.29 seconds
N/A N=57 Insulin-sensitive Obesity: Lessons From Longitudinal Data
Insulin Sensitivity/Resistance · Obesity
Primary: Insulin Sensitivity — 0.0105; -0.0076; 0.0041 micro mol/min/Kg/mU/L/year
N/A N=16 Effect of an EAA/Whey Composition on Protein Metabolism
Sarcopenia
Primary: Protein Anabolism — 3.56; 11.8; 3.02 grams — p=<0.05
N/A N=96 Effect of High Protein Weight Loss for Seniors
Obesity · Weight Loss
Primary: Change in 400 Meter Gait Walk Speed — 0.01; -0.02 meters/second
N/A N=314 Reducing Cardiometabolic Risk and Promoting Functional Health in Older Adults With Obesity and Prediabetes
Obesity · PreDiabetes · Aging
Primary: Change in Bodyweight — -7.4; -6.1 percentage of bodyweight change — p=0.196
Phase 2 N=217 Dose Range Finding Study of Bimagrumab in Sarcopenia
Sarcopenia
Primary: Change From Baseline in Total Short Physical Performance Battery (SPPB) Score to Week 25 — 7.1; 7.3; 7.2; 7.3 Score on a scale — p=0.274
N/A N=132 Effect of Fermented Milk Containing Lactobacillus Casei Strain Shirota in Sarcopenia Elderly
Sarcopenia · Inflammation · Aging
Primary: Impact of LCS on the Change of Gut Microbiota — 0.023577513; 0.248239465; 0.003810442; 0.10325558 % of total Bacteria — p=<0.05
N/A N=187 Utilizing Protein During Weight Loss to Impact Physical Function
Obesity · Weight Loss · Diet Modification
Primary: Change in Expanded Short Physical Performance Battery Score — 0.06; 0.11; 0.16 score on a scale — p=0.16
Phase 2 N=16 Ghrelin Plus Strength Training in Frail Elderly Study
Frailty Syndrome
Primary: Change in the Short Physical Performance Battery (SPPB) — 0.6; 2.4 units on a scale
Phase 3 N=164 Calorie Restriction and Changes in Body Composition, Disease, Function, and Quality of Life in Older Adults
Obesity · Diabetes · Hypertension
Primary: Change in Abdominal Fat Mass — -192.6; -21.9; -275 Cubic cm
Phase 3 N=80 Effect Of Ophiochepalus Striatus Extract On Serum IGF-1 And IL-6 Levels In Elderly Patients With Sarcopenia
Sarcopenia · Geriatric · Muscle Mass
Primary: IGF-1 Levels — 78.92; 77.08 ng/dl